|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 888.60 INR | +1.36% |
|
-3.44% | -3.05% |
| 07/11 | Alivus Life Sciences Limited, Q2 2026 Earnings Call, Nov 07, 2025 | |
| 07/11 | Alivus Life Sciences Limited Reaffirms Earnings Guidance for the Fiscal Year 2026 | CI |
| Capitalization | 11TCr 120.76Cr 103.62Cr 96Cr 90Cr 167.55Cr 180.62Cr 1.11TCr 436.38Cr 5.21TCr 452.89Cr 443.56Cr 19TCr | P/E ratio 2026 * |
20.2x | P/E ratio 2027 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise value | 11TCr 116.53Cr 100Cr 93Cr 87Cr 161.68Cr 174.29Cr 1.07TCr 421.1Cr 5.03TCr 437.03Cr 428.02Cr 18TCr | EV / Sales 2026 * |
4.08x | EV / Sales 2027 * | 3.62x |
| Free-Float |
23.57% | Yield 2026 * |
1.13% | Yield 2027 * | 1.41% |
Last Transcript: Alivus Life Sciences Limited
| 1 day | +1.36% | ||
| 1 week | -3.44% | ||
| Current month | -3.05% | ||
| 1 month | -0.01% | ||
| 3 months | -3.96% | ||
| 6 months | -17.18% | ||
| Current year | -3.05% |
| 1 week | 859.15 |  | 910.25 |
| 1 month | 859.15 | | 928 |
| Current year | 859.15 | | 928 |
| 1 year | 847.2 | | 1,251 |
| 3 years | 370 | | 1,335.1 |
| 5 years | 370 | | 1,335.1 |
| 10 years | 370 | | 1,335.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 60 | 13/08/2019 |
| Director of Finance/CFO | - | 01/06/2022 | |
| Compliance Officer | - | 23/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Yasir Rawjee
BRD | Director/Board Member | 60 | 13/08/2019 |
Manju Agarwal
BRD | Director/Board Member | 68 | 30/10/2020 |
| Director/Board Member | 66 | 08/01/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.36% | -3.44% | -12.79% | +115.52% | 120.76Cr | |
| -0.36% | -3.14% | +44.08% | +196.80% | 96TCr | |
| +2.29% | +5.33% | +50.98% | +26.02% | 53TCr | |
| +0.52% | -4.94% | +26.40% | +44.46% | 39TCr | |
| +0.31% | +1.89% | +30.05% | +17.38% | 37TCr | |
| -0.44% | +0.86% | +34.28% | +22.46% | 30TCr | |
| +0.21% | +2.36% | +28.55% | +35.05% | 28TCr | |
| +2.54% | +2.22% | +11.40% | -1.10% | 28TCr | |
| -1.43% | +0.90% | -38.23% | -21.55% | 26TCr | |
| +1.44% | -3.71% | +23.16% | +21.07% | 18TCr | |
| Average | +0.11% | +0.03% | +19.79% | +45.61% | 35.42TCr | |
| Weighted average by Cap. | -0.18% | +0.04% | +29.94% | +68.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.58TCr 29Cr 25Cr 23Cr 21Cr 40Cr 43Cr 262.43Cr 103.24Cr 1.23TCr 107.15Cr 104.94Cr 4.52TCr | 2.86TCr 32Cr 27Cr 25Cr 24Cr 44Cr 47Cr 291.38Cr 114.63Cr 1.37TCr 118.96Cr 116.51Cr 5.02TCr |
| Net income | 604.67Cr 6.7Cr 5.75Cr 5.35Cr 4.98Cr 9.29Cr 10Cr 62Cr 24Cr 289.25Cr 25Cr 25Cr 1.06TCr | 701.07Cr 7.77Cr 6.66Cr 6.2Cr 5.77Cr 11Cr 12Cr 71Cr 28Cr 335.36Cr 29Cr 29Cr 1.23TCr |
| Net Debt | -381.75Cr -4.23Cr -3.63Cr -3.38Cr -3.14Cr -5.87Cr -6.32Cr -39Cr -15Cr -182.62Cr -16Cr -16Cr -669.15Cr | -535.87Cr -5.94Cr -5.09Cr -4.74Cr -4.41Cr -8.24Cr -8.88Cr -55Cr -21Cr -256.34Cr -22Cr -22Cr -939.3Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | 888.60 ₹ | +1.36% | 38,697 |
| 13/26/13 | 876.70 ₹ | -1.23% | 50,280 |
| 12/26/12 | 887.65 ₹ | +0.85% | 66,352 |
| 09/26/09 | 880.15 ₹ | -2.56% | 83,200 |
| 08/26/08 | 903.25 ₹ | -1.85% | 85,777 |
Delayed Quote NSE India S.E., January 14, 2026 at 06:10 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALIVUS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition